Trial · NCT03484702
Results by group516
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 516
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) Per Independent Review Committee in Cohorts 1, 2 and 3 | Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy | 61.1 | 95% Confidence Interval 43.5 to 76.9 | Percent of Participants | |
| Overall Response Rate (ORR) Per Independent Review Committee in Cohorts 1, 2 and 3 | Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy | 63.0 | 95% Confidence Interval 42.4 to 80.6 | Percent of Participants | |
| Overall Response Rate (ORR) Per Independent Review Committee in Cohorts 1, 2 and 3 | Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 | 70.0 | 95% Confidence Interval 34.8 to 93.3 | Percent of Participants | |
| Overall Response Rate (ORR) Per Investigator in Cohort 4 | Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma | 100 | 95% Confidence Interval 100 to 100 | Percent of Participants | |
| Overall Response Rate (ORR) Per Investigator in Cohort 5 | Cohort 5: Primary Central Nervous System Lymphoma | 80.0 | 95% Confidence Interval 28.4 to 99.5 | Percent of Participants | |
| Number of Participants With Adverse Events in Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | AEs occurring between leukapheresis and lymphodepleting chemotherapy (LDC) | 0 | Participants | |
| Number of Participants With Adverse Events in Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | AEs occurring between LDC and JCAR017 infusion | 2 | Participants | |
| Number of Participants With Adverse Events in Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | AEs occurring between JCAR017 infusion and Day 30 | 9 | Participants | |
| Number of Participants With Adverse Events in Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | AEs occurring between Day 31 and Day 90 | 7 | Participants | |
| Number of Participants With Adverse Events in Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | AEs occurring between Day 91 and end of study | 7 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs) in Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | SAEs occurring between leukapheresis and lymphodepleting chemotherapy (LDC) | 0 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs) in Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | SAEs occurring between LDC and JCAR017 infusion | 0 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs) in Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | SAEs occurring between JCAR017 infusion and Day 30 | 1 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs) in Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | SAEs occurring between Day 31 and Day 90 | 0 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs) in Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | SAEs occurring between Day 91 and end of study | 1 | Participants | |
| Number of Participants With Increase From Baseline in Select Hematology Parameters - Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | Leukocytes (10^9/L) - Day 29 | 0 | Participants | |
| Number of Participants With Increase From Baseline in Select Hematology Parameters - Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | Neutrophils, Segmented (10^9/L) - Day 29 | 2 | Participants | |
| Number of Participants With Increase From Baseline in Select Hematology Parameters - Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | Platelets (10^9/L) - Day 29 | 5 | Participants | |
| Number of Participants With Increase From Baseline in Select Hematology Parameters - Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | Activated Partial Thromboplastin Time (sec) - Day 29 | 0 | Participants | |
| Number of Participants With Increase From Baseline in Select Hematology Parameters - Cohort 7 | Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting | Prothrombin Intl. Normalized Ratio - Day 29 | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03484702/results